Not long after the report of the first targeted disruption of p53 in the mouse, a paper compared the cancer spectrum and incidence between the 129/Sv strain and a mixed C57BL/6+129/Sv strain, finding no significant difference for osteosarcoma specifically [84]. The gene discussed is TP53; the disease is cancer.